AIM
TXG icon

ARK Investment Management’s 10x Genomics TXG Stock Holding History

ARK Investment Management’s Portfolio TXG Stock Details TXG Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$249M Sell
11,717,317
-950,052
-7% -$19M 1.93% 16
2025
Q4 		$207M Buy
12,667,369
+779,973
+7% +$11.8M 1.37% 22
2025
Q3 		$139M Sell
11,887,396
-2,004,707
-14% -$26.1M 0.83% 35
2025
Q2 		$161M Buy
13,892,103
+1,046,390
+8% +$9.54M 1.18% 23
2025
Q1 		$112M Buy
12,845,713
+901,656
+8% +$11.4M 1.12% 27
2024
Q4 		$172M Buy
11,944,057
+1,193,712
+11% +$18.8M 1.43% 21
2024
Q3 		$243M Buy
10,750,345
+1,436,582
+15% +$29.7M 2.22% 12
2024
Q2 		$181M Buy
9,313,763
+3,029,951
+48% +$79.3M 1.61% 21
2024
Q1 		$236M Buy
6,283,812
+2,242,525
+55% +$98.5M 1.63% 19
2023
Q4 		$226M Buy
4,041,287
+1,047,827
+35% +$45.6M 1.34% 22
2023
Q3 		$123M Sell
2,993,460
-120,089
-4% -$6.25M 0.94% 25
2023
Q2 		$174M Sell
3,113,549
-1,041,774
-25% -$56.4M 1.15% 23
2023
Q1 		$232M Sell
4,155,323
-161,244
-4% -$7.53M 1.59% 20
2022
Q4 		$157M Sell
4,316,567
-260,247
-6% -$8.51M 1.36% 23
2022
Q3 		$130M Buy
4,576,814
+973,528
+27% +$37.1M 0.91% 26
2022
Q2 		$184M Buy
3,603,286
+211,948
+6% +$11M 1.09% 24
2022
Q1 		$258M Buy
3,391,338
+730,472
+27% +$63.9M 1.08% 25
2021
Q4 		$396M Sell
2,660,866
-441,085
-14% -$67.6M 1.2% 25
2021
Q3 		$452M Sell
3,101,951
-1,198,086
-28% -$206M 1.08% 25
2021
Q2 		$842M Buy
4,300,037
+795,916
+23% +$144M 1.57% 16
2021
Q1 		$634M Buy
3,504,121
+2,970,625
+557% +$513M 1.26% 21
2020
Q4 		$75.5M Buy
533,496
+302,399
+131% +$43.9M 0.2% 83
2020
Q3 		$28.8M Sell
231,097
-105,456
-31% -$11.1M 0.17% 69
2020
Q2 		$30.1M Buy
+336,553
New +$26.2M 0.32% 49

Other funds holding TXG

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
QCM
Quantinno Capital Management New York $59.9B AUM 28.07% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

ARK Investment Management's TXG Position: Q1 2026 in Review

ARK Investment Management reduced its 10x Genomics (TXG) stake by 7.5% in Q1 2026, selling an estimated $19M and leaving 11,717,317 shares worth $249M. The position accounts for 1.93% of the portfolio, ranked #16.

ARK Investment Management first reported a position in TXG in Q2 2020 and has held it in 24 quarters since. The position peaked at $842M in Q2 2021. 329 funds tracked by Wall St. Rank hold TXG as of Q1 2026.

  • ARK Investment Management held 11,717,317 shares of 10x Genomics worth $249M as of Q1 2026.
  • ARK Investment Management sold 950,052 10x Genomics shares in Q1 2026, an estimated $19M.
  • 10x Genomics made up 1.93% of ARK Investment Management's portfolio in Q1 2026, its #16 holding.
  • ARK Investment Management first reported a position in 10x Genomics in Q2 2020 and has held it in 24 quarters since.
  • ARK Investment Management's 10x Genomics position peaked at $842M in Q2 2021.
  • 329 funds tracked by Wall St. Rank held 10x Genomics as of Q1 2026.

Based on ARK Investment Management's 13F filing for Q1 2026, filed 12 May 2026.